LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Search

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

87.37 -3.38

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

87.37

Максимум

90.01

Ключови измерители

By Trading Economics

Приходи

-8.1M

-56M

Продажби

2.9M

60M

EPS

-0.83

Марж на печалбата

-92.559

Служители

414

EBITDA

-9.7M

-52M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+51.65% upside

Дивиденти

By Dow Jones

Следващи печалби

4.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

151M

6B

Предишно отваряне

90.75

Предишно затваряне

87.37

Настроения в новините

By Acuity

50%

50%

155 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.05.2026 г., 16:33 ч. UTC

Печалби
Значими двигатели на пазара

Webull Shares Slide on 1Q Loss, Soaring Costs

22.05.2026 г., 21:10 ч. UTC

Печалби

These Stocks Are Today's Movers: Dell, Apple, IBM, Estée Lauder, Futu, Rocket Lab, Workday, and More -- Barrons.com

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

22.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

22.05.2026 г., 19:47 ч. UTC

Печалби

Nvidia Has a Plan to Get the Stock Moving Again -- Barrons.com

22.05.2026 г., 19:17 ч. UTC

Пазарно говорене

U.S. Natural Gas Retreats As Weather Outlook Cools -- Market Talk

22.05.2026 г., 19:10 ч. UTC

Пазарно говорене

Oil Futures Edge Up Ahead of U.S. Long Weekend -- Market Talk

22.05.2026 г., 18:54 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

22.05.2026 г., 18:54 ч. UTC

Пазарно говорене

Kroger Seen Narrowing Pricing Gap Versus Walmart -- Market Talk

22.05.2026 г., 18:38 ч. UTC

Пазарно говорене

Canada's Population Slowdown Hits Demand for Consumer Companies -- Market Talk

22.05.2026 г., 18:35 ч. UTC

Придобивния, сливания и поглъщания

IMAX Might Be Exploring a Sale. Who Could Be Buying. -- Barrons.com

22.05.2026 г., 18:09 ч. UTC

Пазарно говорене

Centralized Crypto Lending Slows in 1Q -- Market Talk

22.05.2026 г., 17:58 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Shows Signs of Picking Up -- Market Talk

22.05.2026 г., 17:54 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

22.05.2026 г., 17:54 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

22.05.2026 г., 17:54 ч. UTC

Пазарно говорене

Canada Minister May Be Distancing From Online-Streaming Order -- Market Talk

22.05.2026 г., 17:03 ч. UTC

Пазарно говорене

Canada Spending Obligations on Streamers Is More Severe Beneath Surface -- Market Talk

22.05.2026 г., 16:54 ч. UTC

Пазарно говорене

Crypto Spot Volumes Fall 14% in April -- Market Talk

22.05.2026 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

22.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

22.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

22.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

22.05.2026 г., 16:16 ч. UTC

Пазарно говорене

TSX Growth Driven Almost Entirely by Materials Sector -- Market Talk

22.05.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

22.05.2026 г., 15:55 ч. UTC

Пазарно говорене

Trump Admin Grants Reinforce IBM's Quantum Computing Leadership -- Market Talk

22.05.2026 г., 15:42 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

22.05.2026 г., 15:42 ч. UTC

Пазарно говорене

Oil Continues as Leading Indicator for All Markets -- Market Talk

22.05.2026 г., 15:35 ч. UTC

Пазарно говорене

Gas Prices May Limit Spread of Inflationary Pressures in Canada -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

51.65% нагоре

12-месечна прогноза

Среден 136.77 USD  51.65%

Висок 158 USD

Нисък 105 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

14

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

155 / 345 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat